r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction

• Laura A. Sullivan,

  Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Juliet G. Carbon,

  Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Christina L. Roland,

  Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Jason E. Toombs,

  Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Mari Nyquist-Andersen,

  Affiliation Affitech AS, Oslo Research Park, Oslo, Norway

  ⨯
• Anita Kavlie,

  Affiliation Affitech AS, Oslo Research Park, Oslo, Norway

  ⨯
• Kyle Schlunegger,

  Affiliation Peregrine Pharmaceuticals, Inc., Tustin, California, United States of America

  ⨯
• James A. Richardson,

  Affiliation Departments of Pathology and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Rolf A. Brekken

  * E-mail: rolf.brekken@utsouthwestern.edu

  Affiliations Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯